{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:09:43Z","timestamp":1789207783228,"version":"build-2803163510"},"reference-count":22,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To assess \u03b2-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This was a randomized trial of 58 patients with treatment-na\u00efve newly diagnosed type 2 diabetes. All patients were treated with insulin and metformin for a 3-month lead-in period followed by random assignment to the INS or TOT group. \u03b2-Cell function was assessed using a mixed-meal challenge test at randomization and 6, 12, 18, 30, and 42 months. Analyses were intention to treat and performed with repeated-measures models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Completion rates at 3.5 years were 83% in the insulin group and 72% in the TOT group, with good compliance in both groups (87 \u00b1 20% in the INS group vs. 90 \u00b1 15% in the TOT group). \u03b2-Cell function was preserved at 3.5 years after diagnosis, with no significant change from baseline or difference between the two groups as measured by area under the curve (AUC) of C-peptide (P = 0.14) or the ratio of C-peptide to glucose AUC (P = 0.7). Excellent glycemic control was maintained in both groups (end-of-study HbA1c 6.35 \u00b1 0.84% in the INS group vs. 6.59 \u00b1 1.94% in the TOT group). Weight increased in both groups over time (from 102.2 \u00b1 24.9 kg to 106.2 \u00b1 31.7 kg in the INS group and from 100.9 \u00b1 23.0 kg to 110.5 \u00b1 31.8 kg in the TOT group), with no significant difference between groups (P = 0.35). Hypoglycemic events decreased significantly over time (P = 0.01) but did not differ between groups (P = 0.83).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>\u03b2-Cell function can be preserved for at least 3.5 years with early and intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy after an initial 3-month insulin-based treatment period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc11-2170","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T14:13:13Z","timestamp":1340374393000},"page":"1406-1412","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":82,"title":["\u03b2-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy"],"prefix":"10.2337","volume":"35","author":[{"given":"Lindsay B.","family":"Harrison","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Adams-Huet","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Division of Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Raskin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"key":"2022031221331339700_B1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11892-010-0122-6","article-title":"The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes","volume":"10","author":"Cusi","year":"2010","journal-title":"Curr Diab Rep"},{"key":"2022031221331339700_B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B3","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"2022031221331339700_B4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"\u03b2-Cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031221331339700_B6","first-page":"213","article-title":"Slow response to loss of glycemic control in type 2 diabetes mellitus","volume":"9","author":"Brown","year":"2003","journal-title":"Am J Manag Care"},{"key":"2022031221331339700_B7","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1152\/ajpendo.2000.279.5.E997","article-title":"Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15","volume":"279","author":"Gleason","year":"2000","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221331339700_B8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/diab.34.3.222","article-title":"The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus","volume":"34","author":"Garvey","year":"1985","journal-title":"Diabetes"},{"key":"2022031221331339700_B9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2337\/diacare.20.9.1353","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment","volume":"20","author":"Ilkova","year":"1997","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2337\/diacare.27.5.1028","article-title":"Short-term intensive insulin therapy in newly diagnosed type 2 diabetes","volume":"27","author":"Ryan","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B11","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","article-title":"Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial","volume":"371","author":"Weng","year":"2008","journal-title":"Lancet"},{"key":"2022031221331339700_B12","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2337\/dc08-0075","article-title":"Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy","volume":"31","author":"Chen","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B13","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031221331339700_B14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2310\/6650.2007.06036","article-title":"Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted","volume":"55","author":"Lingvay","year":"2007","journal-title":"J Investig Med"},{"key":"2022031221331339700_B15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc09-0653","article-title":"Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?","volume":"32","author":"Lingvay","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B16","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1152\/ajpendo.2001.281.5.E966","article-title":"Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT","volume":"281","author":"Tura","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221331339700_B17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2337\/diabetes.47.4.606","article-title":"Differentiation between glucose-induced desensitization of insulin secretion and beta-cell exhaustion in the HIT-T15 cell line","volume":"47","author":"Kilpatrick","year":"1998","journal-title":"Diabetes"},{"key":"2022031221331339700_B18","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031221331339700_B19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2337\/diabetes.50.5.1021","article-title":"\u03b2-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death","volume":"50","author":"Finegood","year":"2001","journal-title":"Diabetes"},{"key":"2022031221331339700_B20","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1210\/jc.2002-021181","article-title":"Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility","volume":"88","author":"Juhl","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031221331339700_B21","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2337\/diacare.27.11.2585","article-title":"Effect of rosiglitazone versus insulin on the pancreatic \u03b2-cell function of subjects with type 2 diabetes","volume":"27","author":"Ovalle","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031221331339700_B22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic \u03b2-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/7\/1406\/612878\/1406.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/35\/7\/1406\/612878\/1406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:49:14Z","timestamp":1647128954000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/35\/7\/1406\/30465\/Cell-Function-Preservation-After-3-5-Years-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,6,12]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc11-2170","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,12]]}}}